Publications by authors named "Sari Alon"

Claim this Profile
A
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Myrl Holida, Aleš Linhart, Antonio Pisani, Nicola Longo, François Eyskens, Sari Alon

J Inherit Metab Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Eric L Wallace, Ozlem Goker-Alpan, William R Wilcox, Myrl Holida, John Bernat, Sari Alon

J Med Genet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Derralynn Hughes, Derlis Gonzalez, Gustavo Maegawa, John A Bernat, Myrl Holida, Sari Alon

Genet Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Aleš Linhart, Gabriela Dostálová, Kathy Nicholls, Michael L West, Camilla Tøndel, Sari Alon

Orphanet J Rare Dis· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial.
Einat Almon, Yoseph Shaaltiel, Wisam Sbeit, Alex Fich, Doron Schwartz, Sari Alon, Alona Paz

J Clin Gastroenterol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
Ari Zimran, Gloria Durán, Pilar Giraldo, Hanna Rosenbaum, Fiorina Giona, Sari Alon

Blood Cells Mol Dis· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
Raphael Schiffmann, Ozlem Goker-Alpan, Myrl Holida, Pilar Giraldo, Laura Barisoni, Alona Paz, Sari Alon

J Inherit Metab Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems-The taliglucerase alfa story.
Bonita Rup, Sari Alon, Bat-Chen Amit-Cohen, Einat Brill Almon, Raul Chertkoff

PLoS One· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy.
Einat Almon, Tawfik Khoury, Ariel Drori, Svetlana Gingis-Velitski, Sari Alon

J Immunol Methods· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
Richat Abbas, Glen Park, Bharat Damle, Raul Chertkoff, Sari Alon

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R.
Jacob Atsmon, Einat Brill-Almon, Carmit Nadri-Shay, Raul Chertkoff, Sari Alon

Toxicol Appl Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis